Firdapse (amifampridine) product summary, patent information, and competitor products (marketed and new therapies) are all included in this report. In addition, the report highlights historical and projected revenue from 2020 to 2030.
The DelveInsight report, “Firdapse (amifampridine) Drug Insight and Market Forecast, 2030,” delves into the specifics of Firdapse (amifampridine), a drug used to treat Lambert-Eaton myasthenic syndrome (LEMS) in adults.
Firdapse (amifampridine) product summary, patent information, and competitor products (marketed and new therapies) are all included in this report. In addition, the report highlights historical and projected revenue from 2020 to 2030.
Some Crucial Highlights from the Firdapse (amifampridine) Drug Insight Report
-
Firdapse is a nonspecific, voltage-dependent potassium (K+) channel blocker that induces presynaptic membrane depolarization and delays or prevents repolarization.
-
Catalyst Pharmaceuticals and KYE Pharmaceuticals announced an exclusive licence agreement in August 2020, under which KYE Pharmaceuticals will commercialise Firdapse in Canada.
-
Catalyst Pharmaceuticals announced in May 2019 that it had revised its Firdapse licence agreement to broaden the commercial territory for the drug. The licence was originally only for North America, but it has since been expanded to include Japan.
-
Apart from Firdapse, there is another drug Ruzurgi (Jacobus Pharmaceutical), which is available in the market for treating LEMS.
-
Among the emerging therapies for LEMS, SHX-003 (Shenox Pharmaceuticals) is still in the discovery phase of development.
-
Key companies which are involved in treating LEMS are Catalyst Pharmaceuticals, KYE Pharmaceuticals, Jacobus Pharmaceutical, Shenox Pharmaceuticals, among others.
Learn more by requesting sample @ Firdapse (amifampridine) Drug Insights and Market Forecast Report
Firdapse (amifampridine) (Catalyst Pharmaceuticals): Product Profile
Product Description
Firdapse (amifampridine) 10 mg tablets are a nonspecific, voltage-dependent potassium (K+) channel blocker that induces presynaptic membrane depolarization and delays or prevents repolarization. This action causes slow voltage-dependent calcium (Ca2+) channels to open, allowing for a subsequent Ca2+ influx. As a result, it causes synaptic vesicles containing Acetylcholine (ACh) to exocytose, releasing more ACh into the synaptic cleft, improving neuromuscular transmission and muscle function. Lambert-Eaton myasthenic syndrome (LEMS) in adults may be treated with Firdapse (amifampridine).
Seizures, severe allergic reactions, such as anaphylaxis, are possible side effects of Firdapse. Firdapse has the potential to cause severe allergic reactions. Tingling in the mouth, tongue, face, fingers, toes etc. are the most common Firdapse side effects.
Dosage Forms and Strengths
Firdapse tablets are white to off-white, round, and functionally scored tablets that contain 10 mg amifampridine. Each tablet is embossed with “CATALYST” on the non-scored side and “211” above the score and “10” below the score on the scored side.
Research and Development Activities
In two randomised, double-blind, placebo-controlled discontinuation trials, Firdapse’s efficacy for the treatment of LEMS was demonstrated. A total of 64 adults with LEMS (ages 21 to 88) were enrolled in Study 1 (NCT01377922) and Study 2 (NCT02970162). Patients with a verified diagnosis of LEMS based on neurophysiology tests or a positive anti-P/Q type voltage-gated calcium channel antibody test were enrolled in the studies. The improvement in the Quantitative Myasthenia Gravis (QMG) score and the Subject Global Impression (SGI) score from baseline to the end of the discontinuation period were the two co-primary efficacy indicators in both studies.
For more information about drug visit Firdapse Product Profile
Key Companies
-
Catalyst Pharmaceuticals
-
KYE Pharmaceuticals
-
Jacobus Pharmaceutical
-
Shenox Pharmaceuticals
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)
Study Period: 2017-30
Key Companies: Catalyst Pharmaceuticals, KYE Pharmaceuticals, Jacobus Pharmaceutical, Shenox Pharmaceuticals among others.
Tools Used: SWOT Analysis
Analyst’s Views
Table of Contents
|
1. |
Firdapse: Background & Overview |
|
2. |
Firdapse: Marketed Competitor Product Profiles |
|
3. |
Emerging Competitor Product Profiles |
|
4. |
Firdapse: 7MM Market Analysis |
|
5. |
Firdapse- Market Dynamics |
|
6. |
Firdapse Patent Details |
|
7. |
SWOT Analysis |
|
8. |
Firdapse- Future Perspectives and Conclusion |
|
9. |
Appendix |
|
10. |
About DelveInsight |
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Related Reports
177-LUTETIUM-PSMA-617- Emerging Drug Market
DelveInsight’s “177-LUTETIUM-PSMA-617- Emerging Drug Insight and Market Forecast – 2030” report provides comprehensive insights about an investigational product for Prostate cancer in 7 Major Markets. A detailed picture of the 177-LUTETIUM-PSMA-617 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/